BMJ Open CT-diagnosed emphysema and prognosis of chronic airflow obstruction: a retrospective study

Kazuyoshi Kurashima,¹ Chiaki Fukuda,¹ Keitaro Nakamoto,¹ Yotaro Takaku,¹ Naoya Hijikata,¹ Toshiko Hoshi,² Tetsu Kanauchi,² Miyuki Ueda,² Noboru Takayanagi,¹ Yutaka Sugita,¹ Ryuichiro Araki³

To cite: Kurashima K, Fukuda C, Nakamoto K, *et al.* CT-diagnosed emphysema and prognosis of chronic airflow obstruction: a retrospective study. *BMJ Open* 2013;**3**:e003541. doi:10.1136/bmjopen-2013-003541

► Prepublication history and additional material for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2013-003541>).

Received 4 July 2013

Revised 9 September 2013

Accepted 24 September 2013

CrossMark

¹Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama, Japan

²Department of Radiology, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama, Japan

³Community Health Science Center, Saitama Medical University, Moroyama-machi, Saitama, Japan

Correspondence to

Dr Kazuyoshi Kurashima; kurashima.kazuyoshi@pref.saitama.lg.jp

ABSTRACT

Objective: CT-diagnosed emphysema is associated with poor prognosis in chronic obstructive pulmonary disease (COPD). Its clinical impacts on prognoses of asthma with chronic airflow obstruction (CAO) are not well known. We sought to compare mortalities and prognostic factors in COPD and asthma with CAO by the presence or absence of CT-diagnosed emphysema.

Design: Retrospective cohort study.

Setting: Referral centre hospital for respiratory disease.

Participants: 1272 patients aged over 40 years with CAO (January 2000 to December 2011). CAO was defined as a forced expiratory volume in 1 s/forced vital capacity <0.7 after bronchodilator use throughout the observation period.

Primary and secondary outcome measurements:

Overall mortality served as the primary endpoint. We compared mortalities and prognostic factors of COPD and asthma subgroups with or without emphysema. Secondary endpoints were the prevalence of COPD and asthma in patients with CAO.

Results: Overall, diagnoses included COPD with emphysema in 517 (40.6%) patients, COPD without emphysema in 104 (8.2%) patients, asthma with emphysema in 178 (13.9%) patients, asthma without emphysema in 169 (13.3%) patients, other respiratory diseases (RD) with emphysema in 128 (10.1%) patients, and other RD without emphysema in 176 (13.8%) patients. Patients with asthma without emphysema had the best prognosis followed by those with asthma with emphysema, COPD without emphysema and COPD with emphysema. Each subgroup had distinct prognostic factors. Presence of emphysema was an independent risk factor for de novo lung cancer among patients with CAO.

Conclusions: Patients with asthma with CAO have a better prognosis than patients with COPD. The presence of CT-diagnosed emphysema predicts poor prognosis in COPD and asthma with CAO.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by not fully reversible airflow obstruction in patients with risk

Strengths and limitations of this study

- This will be the first study to compare prognosis of the subgroups of chronic obstructive pulmonary disease and asthma with chronic airflow obstruction (CAO) divided by the CT scan findings of emphysema.
- The prognosis of asthma with CAO was evaluated in the period after inhaled corticosteroids had become first-line therapy for asthma.
- This is a large-scale cohort study, but the data are derived from a single centre and the study is retrospective.

factors (tobacco, occupation and air pollution).¹ It is also recognised that various respiratory diseases (RD) other than COPD such as asthma, bronchiectasis or old tuberculosis may have similar chronic airflow obstruction (CAO) as a postbronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) persistently under 0.7.^{2–4} Recently, it has been recognised that emphysematous change as assessed by high-resolution CT (HRCT) scan is a more important prognostic factor than FEV1 in patients with COPD.⁵ However, the clinical significance of HRCT-diagnosed emphysema in the prognosis of other RD such as asthma with fixed airflow obstruction is not well known.

We hypothesised that HRCT-diagnosed emphysema is associated with the prognosis of the patients with CAO not limited to patients with COPD. We sought to compare the prognosis and prognostic factors of the phenotypes of COPD and asthma with CAO classified by the HRCT findings of emphysema. We also examined the prevalence of these phenotypes and other RD in consecutive patients with CAO to clarify the impact of differentiating these phenotypes.

METHODS

Patients

We reviewed 1960 consecutive patients older than 40 years of age with initial postbronchodilator FEV₁/FVC < 0.7 who presented to the Saitama Cardiovascular and Respiratory Center (a tertiary referral centre with 155 beds for RD) in Saitama, Japan, from 2000 through 2011. CAO was defined to be an FEV₁/FVC ratio of < 0.7 after bronchodilator use throughout the observation period. We excluded 326 (16.6%) patients who did not undergo an HRCT examination or who did not receive a complete diagnosis, 133 (6.8%) patients who had lung cancer at the entry examination, and 229 (11.7%) patients whose postbronchodilator FEV₁/FVC recovered to > 0.7 during the observation period. Finally, we studied 1272 patients with CAO who underwent an HRCT examination.

Study design

This was a retrospective cohort study in which clinical data were collected from medical records. Survival status was obtained from medical records and/or telephone interviews.

All deaths were classified into the following five groups: (1) primary RD, (2) lung cancer, (3) malignancy other than lung cancer, (4) respiratory infectious diseases and (5) other or unknown. The HRCT study was ordered by the chest physician in charge for a closer examination of symptoms or evaluation of the diseases. The algorithm used to classify CAO is shown in online supplementary figure S1. All tests involved in the study were taken in a stable phase, with no evidence of any exacerbations for at least 6 weeks. HRCT images obtained within 6 months of the initiation time were considered acceptable for the evaluation. Medications used from the start of the observation period were also recorded.

The criteria used to classify patients with CAO included the following: (1) COPD with emphysema: presence of macroscopic emphysema on HRCT with a smoking history of at least 10 pack-years without other respiratory complications; (2) COPD without

emphysema: no macroscopic emphysema on HRCT with a smoking history of at least 10 pack-years without other respiratory complications; (3) asthma with emphysema: presence of macroscopic emphysema on HRCT and fit the criteria for asthma⁶; asthma symptoms or history, a postbronchodilator increase in FEV₁ of > 12% and 200 mL, evidence of at least one of the following, sputum eosinophilia (> 3%) or increased exhaled nitric oxide (> 30 ppb) or evidence of atopy; (4) asthma without emphysema: no macroscopic emphysema on HRCT and fit the above criteria for asthma; (5) other RD with emphysema: presence of macroscopic emphysema on HRCT and fulfil the criteria for other RD except asthma; and (6) other RD without emphysema: no macroscopic emphysema on HRCT and presence of other RD except asthma. Special care was taken to diagnose possible lung diseases by respiratory specialists and radiology specialists in our clinic for more than a decade, and all the necessary complementary tests were performed in this respect. Old pulmonary tuberculosis and pneumoconiosis were diagnosed by CT findings and history. Non-tuberculous mycobacterial lung diseases were diagnosed by the 2007 American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) diagnostic criteria.⁷ Chronic hypersensitivity pneumonitis,⁸ diffuse panbronchiolitis,⁹ pulmonary Langerhans cell histiocytosis,¹⁰ sarcoidosis,¹¹ bronchial diseases due to rheumatoid arthritis,¹² bronchiolitis obliterans¹³ and other miscellaneous diseases were diagnosed as previously described.

High-resolution CT

HRCT scans were performed in full inspiration with a HiSpeed Advantage CT scanner (GE Medical Systems, Milwaukee, Wisconsin, USA) with a slice thickness of 1 mm, scanning time of 1 s, voltage of 140 kV, tube current of 200 mA and field of view of 20 cm. The presence of emphysema was defined as well-demarcated areas of decreased attenuation in comparison with a contiguous normal lung and marginated by a very thin or no wall with upper zone predominance. The presence of emphysema and CT diagnosis were determined

Figure 1 Phenotypes of chronic airflow obstruction (CAO).

CAO was defined as postbronchodilator FEV₁/FVC < 0.7 throughout the observation period. Patients were classified by the high-resolution CT findings of emphysema and other clinical examinations. FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.

by two radiologists with extensive experience in the diagnosis of RD; all were blind to other researchers. The CT findings of usual interstitial pneumonia or other interstitial pneumonia were diagnosed based on the 2002 ATS/European Respiratory Society (ERS) classification.¹⁴ The presence of bronchiectasis was based on criteria by Naidich *et al*.¹⁵ Mild dilation of the airways in COPD was not considered as bronchiectasis.

Pulmonary function tests

Pulmonary function tests were performed with a CHESTAC-8800 spirometer (Chest MI Corp, Tokyo, Japan). Predicted values of spirometric measurements were derived from the guidelines for pulmonary function tests issued by the ATS.¹⁶ Spirometry was performed before and 30 min after inhalation of 200 µg of salbutamol, and the data obtained after inhalation of salbutamol were used for evaluation.

Statistical analysis

Categorical baseline characteristics are summarised by per cent, and continuous characteristics are reported as mean±SD. Comparisons between subgroups for descriptive summaries were performed by analysis of variance. We compared the baseline characteristics to investigate potential risk factors of mortality. We chose the variables for entry into univariate Cox regression analysis from the results that showed significant effectors with previously recognised clinical significance: clinical phenotype, sex, age, body mass index (BMI), smoking history (1 cigarette/year), current smoking, FVC, FEV1, FEV1/FVC, FEV1 reversibility to bronchodilators, annual change in FEV1 and medications used from the start of observation. We then performed multivariate Cox regression analysis with backward variable selection.

Survival in each patient subgroup was estimated by the Kaplan-Meier analysis. Mortality rates from any cause for two clinical phenotypes were compared with a log-rank test. Time was defined from initial examination until 1 March 2012 or until death or loss to follow-up before 1 March 2012.

Differences in causes of mortality were analysed by the Fisher-Freeman-Halton test, and risk for de novo lung cancer was analysed by multiple logistic regression analysis with Firth's bias reduction. A p value of <0.05 was considered statistically significant. All data were analysed with SAS V.9.1.3 SP4 (SAS Institute Inc, Cary, North Carolina, USA).

RESULTS

Prevalence of COPD, asthma and other RD in patients with CAO

Of the 1272 patients with postbronchodilator FEV1/FVC<0.7 throughout the observation period, 517 (40.6%) had COPD with emphysema, 104 (8.2%) had COPD without emphysema, 178 (14%) had asthma with emphysema, 169 (13.3%) had asthma without

emphysema, 128 (10%) had other RD with emphysema and 176 (13.8%) had other RD without emphysema (figure 1). Other RD with or without emphysema are shown in online supplementary table S1.

Patient characteristics

The patient characteristics of each group are shown in table 1. In total, 176 (13.8%) patients were women, and 1131 (88.9%) patients had a smoking history. All of the patients with COPD and all of the patients with emphysema had smoking histories. Patients with COPD with emphysema had the lowest BMI. The mean %FEV1 was lowest in patients with asthma with emphysema. The annual decline of FEV1 was largest in the patients with asthma with emphysema subgroup and smallest in the patients with COPD without emphysema subgroup.

Mortalities of CAO phenotypes

The survival curves and rates for the patient subgroups are shown in figure 2 and online supplementary table 2, and the prognostic factors of overall patients are summarised in online supplementary table S3. Although other RD with or without emphysema are a mixture of miscellaneous diseases, their survival curves were also presented in figure 2 for reference. Patients with asthma had better overall survival than patients with COPD when adjusted for other potential variables (see online supplementary table S3).

Patients with asthma and no emphysema had the best prognosis followed by those with asthma with emphysema, COPD without emphysema and COPD with emphysema. Overall survivals between patients with COPD with or without emphysema, and overall survivals between patients with asthma or without emphysema were significantly different by log-rank test (p=0.004 and p=0.016, respectively). Even when adjusted for potential variables, the presence of emphysema was a significant predictor of death in COPD but not in asthma (see online supplementary table S4).

Mortality risks from any cause for each clinical subtype except for other RD are shown in table 2. Age, BMI and %FVC were independent prognostic factors in COPD with emphysema, whereas age and %FVC were the independent prognostic factors for COPD without emphysema. In the asthma with emphysema subgroup, low %FEV1 and presence of wheezing were negative prognostic factors. In the asthma without emphysema subgroup, age and use of inhaled corticosteroids (ICSs) were significant prognostic factors.

Causes of mortality and de novo lung cancer

There were significant differences in the causes of mortality among the subgroups (Fisher's statistic was 23.59, and the double-sided p value was 0.020, table 3). In the COPD with emphysema subgroup, about one-third of the causes of death were de novo malignant diseases and about one-fourth of the cause of death was lung cancer. During the observation period, de novo lung

Table 1 Characteristics of the patients with chronic airflow obstruction

Emphysema	COPD		Asthma		Other RD		p Value
	Yes	No	Yes	No	Yes	No	
Number	517, 40.6%	104, 8.2%	178, 13.9%	169, 13.3%	128, 10.1%	176, 13.8%	
Age	69.1±8.3	70.4±7.2	67.6±7.9	64.5±9.5	70.6±7.9	65.0±11.8	<0.001
Female sex (n, %)	20, 3.9	10, 9.6	21, 11.8	55, 32.7	4, 3.1	66, 37.5	<0.001
Body mass index	21.2±3.6	23.2±2.6	21.9±3.3	23.0±3.2	22.2±3.6	22.3±3.3	<0.001
Never smoker (n, %)	0	0	0	62, 36.9	0	79, 44.9	<0.001
Smoking index (pack-year)	67.2±34.7	57.6±28.3	59.3±29.0	22.9±24.5	65.8±34.1	20.5±25.4	<0.001
%FVC	85.5±19.4	86.4±18.9	86.0±19.2	86.1±18.4	84.6±22.1	76.4±18.5	<0.001
%FEV1	59.6±24.4	71.2±21.9	56.0±21.8	66.5±22.1	70.6±28.5	65.7±21.3	<0.001
FEV1/FVC	44.7±12.7	53.3±9.9	44.4±11.9	52.7±11.1	53.2±12.8	56.0±11.8	<0.001
Reversibility, per cent	8.1±8.1	7.7±7.6	17.7±13.0	17.1±12.3	6.8±7.4	9.5±10.6	<0.001
Reversibility, mL	95.2±85.8	108.4±96.5	194.4±139.4	218.0±158.8	96.2±92.9	117.4±120.8	<0.001
Δ FEV1 (mL/year)	−34.4±69.8	−12.9±69.2	−50.2±59.0	−12.1±114.5	−42.8±73.3	−31.1±93.4	0.002
Medication (n, %)							
Long-acting β 2-receptor agonist	164, 31.7%	31, 29.8%	93, 52.2%	122, 72%	7, 5.5%	12, 6.8%	<0.001
Long-acting muscarinic receptor antagonist	181, 35.0%	29, 27.9%	48, 27.0%	4, 2.4%	17, 13.3%	4, 2.3%	<0.001
Inhaled corticosteroids	142, 27.5%	42, 40.4%	129, 72.5%	152, 89.9%	16, 12.5%	27, 15.3%	<0.001
Methylxanthine	60, 11.6%	13, 12.5%	37, 20.8%	22, 13.1%	22, 17.2%	12, 6.8%	<0.001
Observation period (year)	4.3±2.9	4.6±3.2	5.8±3.2	5.9±3.0	4.1±2.8	4.2±2.8	<0.001

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.

Figure 2 Kaplan-Meier survival curves for phenotypes of chronic airflow obstruction. Prognoses between patients with COPD with or without emphysema, and prognoses between patients with asthma with or without emphysema were significantly different by log-rank test ($p=0.004$ and $p=0.016$, respectively). COPD, chronic obstructive pulmonary disease; RD, respiratory diseases.

cancers were observed in 38/517 (7.7%) in COPD with emphysema, 5/104 (4.8%) in COPD without emphysema, 4/178 (2.2%) in asthma with emphysema, 2/168 (1.1%) in asthma without emphysema, 8/128 (6.25%) in other RD with emphysema and 3/176 (1.7%) in other RD without emphysema. Therefore, we analysed the risk of de novo lung cancer for the 1272 patients with CAO (table 4). The presence of emphysema was a significant predictor for de novo lung cancer (HR 2.055, 95% CI 1.042 to 4.053; $p=0.038$), and asthma was a negative predictor for de novo lung cancer (HR 0.349, 95% CI 0.143 to 0.849; $p=0.020$).

DISCUSSION

Patients with CAO, postbronchodilator FEV1/FVC always below 0.7, are often diagnosed just as COPD and treated similarly. In this study, we classified the patients with CAO into COPD/asthma/other RD, and then subdivided them by the CT scan findings of emphysema. We showed that COPD comprised only about half of the patients with CAO, and each subgroup had distinct prognosis and prognostic factors. Prognosis of the patients with asthma was better than that of COPD in patients with CAO, and the presence of emphysema was associated with poor prognosis in COPD and asthma. In addition, the presence of emphysema and the presence of asthma were positive and negative risk factors for de novo lung cancer, respectively, in patients with CAO. These data clearly show the impact of differential diagnosis of COPD and usefulness of CT-diagnosed emphysema for the management of patients with CAO.

This study was a retrospective but large-scale single-centre study. In 2000, we introduced a diagnostic algorithm for the patients who showed postbronchodilator FEV1<0.7.¹⁷ HRCT was used to diagnose the presence of emphysema, possible lung cancer, interstitial changes in

any lung field, bronchiectasis and miscellaneous diseases of specific clinical entities. Although the present study is retrospective, there is an advantage for diagnosis by having long-term clinical records including responses to ICS treatments. This would be important for diagnosing asthma with similar lung functions to COPD because the presence of intermittent wheezing, variability in the peak flow rate or responses to ICSs might be identified in a follow-up period after initial diagnosis. Sputum eosinophilia and an elevated level of exhaled nitric oxide are well-established markers to distinguish asthma from COPD once fixed airflow obstruction has developed.^{18 19} We examined these markers to diagnose allergic asthma.

COPD has been thought to be an overlap between chronic bronchitis, emphysema and asthma, and this concept was represented in a Venn diagram and recognised by the ATS.^{20 21}

We observed that a part of the patients with COPD had no emphysema as best diagnosed by HRCT and careful differential diagnoses. It is not clear whether they have microscopic emphysema, but they had distinct prognosis and prognostic factors from that of COPD with emphysema. The coexistence of asthma and COPD is known as the overlap syndrome.^{22 23} The overlap syndrome of asthma and COPD has been defined by the coexistence of increased variability of airflow in a patient with incompletely reversible airway obstruction.²³ By this definition, all patients with asthma recruited in this study are considered to be a part of the overlap syndrome. In this study, we further classified asthma with CAO by the presence of emphysema. We found that the presence of emphysema predicted poor overall survival in patients with asthma with CAO. Although HR was not significant when adjusted by other potential variables, these subgroups had distinct prognostic factors. In patients with asthma and emphysema, their survival was predicted by the severity of airflow obstruction at a stable period, whereas in patients with asthma without emphysema, the use of ICSs was a critical factor for prognosis regardless of airflow obstruction in a stable state.

Recently, emphysema with the usual interstitial pneumonia or other interstitial pneumonia has attracted as much attention as combined pulmonary fibrosis with emphysema.²⁴ Other RD with or without emphysema comprised 23% of the patients with CAO. HRCT is also useful to detect respiratory comorbidities and other RD. For example, HRCT is sensitive to diagnose interstitial shadows or small airway disease in patients with rheumatoid arthritis.²⁵ However, because these groups are a mixture of miscellaneous diseases, they are not considered as one group. Therefore, we only showed their survival curves just for reference purposes.

One of the main findings of this study is that patients with asthma with CAO had a significantly better prognosis than those with COPD. It is well accepted that disease in patients with asthma who develop incompletely

Table 2 Univariate and multivariate analysis of the risk of mortality in subgroups

Subgroup Variable	Univariate Cox regression			Multivariate Cox regression final model		
	Crude HR	95% CI	p Value	Adjusted HR	95% CI	p Value
COPD with emphysema						
Age, per 1 year increase	1.056	1.024 to 1.089	<0.001	1.038	1.003 to 1.074	0.033
BMI, per 1 unit increase	0.853	0.792 to 0.917	<0.001	0.904	0.835 to 0.978	0.012
%FVC, per 1% increase	0.967	0.956 to 0.978	<0.001	0.965	0.947 to 0.983	<0.001
%FEV1, per 1% increase	0.978	0.968 to 0.988	<0.001			
FEV1 reversibility, per 1 mL increase	0.995	0.992 to 0.998	0.002			
Use of LABA						
None	Reference	—	—			
Positive	0.628	0.398 to 0.992	0.046			
Use of LAMA						
None	Reference	—	—			
Positive	0.547	0.353 to 0.849	0.007			
COPD w/o emphysema						
Age, per 1 year increase	1.152	1.003 to 1.323	0.045	1.236	1.031 to 1.482	0.022
%FVC, per 1% increase	0.952	0.920 to 0.985	0.004	0.918	0.854 to 0.985	0.018
%FEV1, per 1% increase	0.964	0.854 to 0.997	0.030			
Asthma with emphysema						
%FEV1, per 1% increase	0.952	0.923 to 0.983	0.002	0.941	0.905 to 0.979	0.002
Wheezing						
None	Reference	—	—	Reference	—	—
Positive	1.431	1.129 to 1.812	0.003	1.654	1.236 to 2.213	0.001
Age, per 1 year increase	1.079	1.003 to 1.161	0.041			
FEV1 reversibility, per 1 mL increase	0.994	0.990 to 0.999	0.015			
Asthma w/o emphysema						
Age, per 1 year increase	1.174	1.047 to 1.316	0.006	1.186	1.008 to 1.394	0.039
Use of ICSs						
None	Reference	—	—	Reference	—	—
Positive	0.091	0.015 to 0.540	0.008	0.091	0.014 to 0.594	0.012
%FVC, per 1% increase	0.938	0.883 to 0.997	0.038			

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICSs, inhaled corticosteroids; LABA, long-acting β 2-adrenergic receptor agonist; LAMA, long-acting muscarinic receptor antagonist; w/o, without.

reversible airflow obstruction resembles COPD in terms of age, airway complications and the pattern of airway inflammation with increased presence of airway

neutrophils.^{26–29} The data of this study seem rather surprising because asthma patients with emphysema had the lowest baseline FEV1 and largest annual decline of

Table 3 Mortality causes in the study groups

	COPD with emphysema	COPD without emphysema	Asthma with emphysema	Asthma without emphysema	Other RD with emphysema	Other RD without emphysema	p Value
Primary respiratory causes	34 (35.7%)	5 (62.5%)	6 (37.5%)	2 (40%)	15 (51.7%)	7 (33.3%)	0.020
Lung cancer	22 (23.1%)	0	1 (6.3%)	0	3 (10.3%)	2 (9.5%)	
Other malignant diseases	10 (10.5%)	0	1 (6.3%)	0	1 (3.4%)	0	
Respiratory infectious diseases	6 (6.3%)	1 (12.5%)	3 (18.7%)	0	2 (6.9%)	7 (33.3%)	
Other causes/unknown	23 (24.2%)	2 (25.0%)	5 (31.2%)	3 (60%)	8 (27.6%)	5 (23.8%)	
Total number	95	8	16	5	29	21	

COPD, chronic obstructive pulmonary disease; RD, respiratory diseases.

Table 4 Univariate and multivariate analysis of the risk of de novo lung cancer

Variables	Crude OR	95% CI	p Value	Adjusted OR (all variables)	95% CI	p Value	Adjusted OR (selected variables)	95% CI	p Value
Sex									
Female	Reference								
Male	2.088	0.787 to 5.540	0.139	0.946	0.343 to 2.608	0.914			
Age, per 1 year increase	1.037	1.004 to 1.071	0.027	1.028	0.994 to 1.064	0.108	1.026	0.993 to 1.060	0.1196
Smoking history, per 1 cigarette/year	1.000	1.000 to 1.000	0.003	1.000	0.999 to 1.001	0.171			
BMI, per 1 unit increase	1.007	0.996 to 1.018	0.231	1.008	0.993 to 1.024	0.288			
%FVC, per 1% increase	1.001	0.989 to 1.013	0.845	1.007	0.989 to 1.024	0.462			
%FEV1, per 1% increase	0.998	0.989 to 1.007	0.641	0.999	0.985 to 1.014	0.9153			
Emphysema	2.602	1.324 to 5.116	0.006	1.513	0.681 to 3.363	0.309	2.055	1.042 to 4.053	0.038
COPD	2.367	1.171 to 4.785	0.016	1.125	0.439 to 2.887	0.806			
Asthma	0.277	0.114 to 0.672	0.046	0.356	0.144 to 0.885	0.262	0.349	0.143 to 0.849	0.020
Other RD	0.731	0.379 to 1.409	0.350	0.835	0.408 to 1.710	0.622			

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.

FEV1 among patients with CAO. A previous report showed that the prognosis of patients with COPD with airway hyper-responsiveness was worse than that of patients with COPD without airway hyper-responsiveness.³⁰ In that study, which was published in 2000, the patients were recruited from the 1960s to the 1970s, a period before ICSs had become first-line therapy for asthma. In addition, death by lung cancer was accumulated in COPD. It could partially explain the poorer prognosis of COPD compared to asthma with CAO.

In a previous prospective study, published in 2010, the extent of emphysema was associated with COPD prognosis.⁵ Another study showed that emphysema severity is independently associated with a rapid annual decline in FEV1 in patients with COPD.³¹ Although the definition of emphysema subgroups is different from that of previous studies,^{5, 31} the results of this study are in accordance with these reports in that the survival rate and annual decline in COPD without emphysema were better than those in COPD with emphysema ($p=0.004$ by log-rank test, and $p=0.008$ by Mann-Whitney test, respectively). Low body weight was a poor prognostic factor in patients with COPD with emphysema, but not in patients with COPD without emphysema.

Lung cancer is an important cause of mortality in COPD, and in a recent large cohort study, older age, low BMI, early global initiative for chronic obstructive lung disease stage and low diffusion capacity for carbon monoxide (DLco) were independent risk factors for de novo lung cancer in COPD.³² Among the patients with CAO, we showed that emphysema was a positive risk factor for lung cancer ($HR=2.06$) and asthma was a negative risk factor ($HR=0.35$). The result of asthma should be inter-related with caution because it might reflect increased risk for lung cancer in patients without asthma (COPD plus other RD). In fact, recent meta-analysis showed that the relative risk for lung cancer associated with asthma was 1.28.³³ However, knowledge of the relative risks for lung cancer may be helpful for the follow-up of patients with CAO.

There are several limitations that should be noted. This study was retrospective, and therefore some clinical and laboratory findings were not available. We could measure residual volume (RV), total lung capacity (TLC) and low DLco in only a portion of the patients at the start of observation; therefore, we excluded these parameters from the analysis of prognosis. In this study, %FVC was a stronger prognostic factor than %FEV1 in patients with COPD, although they were very similar in univariate analysis. %FVC was most closely correlated with RV/TLC ($r=-0.730$, $p<0.001$) among pulmonary function parameters, so reduced %FVC might reflect increased RV/TLC in COPD. In this study, bronchiectasis was diagnosed in a very strict sense.¹⁵ Mild dilation of the bronchi in COPD was not considered. Our data are in discordance with a previous report demonstrating the high prevalence of bronchiectasis in COPD.³⁴ If we

found real bronchiectasis, we made strong efforts to find a more specific diagnosis such as old tuberculosis, non-tuberculous mycobacterial lung diseases, diffuse pan-bronchiolitis, bronchial diseases due to rheumatoid arthritis, bronchiolitis obliterans and so on.

In conclusion, patients with not fully reversible airflow obstruction are heterogeneous. Prognosis of the patients with asthma with CAO was better than that of those with COPD in spite of the similar age and lung functions. The presence of emphysema is associated with poor prognosis in COPD and in asthma with CAO. Recognition of HRCT findings of emphysema and allergic asthma in patients with CAO would be important because clinicians could have different strategies for these conditions. The data of this study suggest that the use of ICSs and control of airway obstruction are critically important for the prognosis of asthma with CAO. In patients with COPD with emphysema, preserved body weight and lung functions were important for prognosis, but de novo lung cancer should be considered regardless of age and degree of airflow obstruction.

Acknowledgements The authors would like to thank Chie Ohta, Daido Tokunaga, Yousuke Miyahara, Nao Kagiya, Takashi Ishiguro and Tsutomu Yanagisawa for providing treatment and care for study patients.

Contributors KK designed the study and wrote the manuscript. CF, KN, YT, NH, NT and YS acquired the clinical data. TH, TK and MU analysed the CT findings. RA analysed the data.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Ethics approval The study was approved by the Institutional Review Board of Saitama Cardiovascular and Respiratory Center (IRB No. 2012001).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Distribution and statistical difference graphs of annual decline of forced expiratory volume in 1 s (FEV1), FEV1 reversibility, relationships of FEV1 or forced vital capacity to low diffusion capacity for carbon monoxide, and residual volume are available by email to the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. From the *Global Strategy for the Diagnosis, Management and Prevention of COPD*, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. <http://www.goldcopd.org/> (accessed 12 Dec 2012).
2. Anonymous. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. A report of the conclusions of the Ciba guest symposium. *Thorax* 1959;14:286–99.
3. Rabe KF, Hurd S, Anzueto A, *et al.* Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;176:532–55.
4. Shirlcliffe P, Weatherall M, Travers J, *et al.* The multiple dimensions of airways disease: targeting treatment to clinical phenotypes. *Curr Opin Pulm Med* 2011;17:72–8.
5. Haruna A, Muro S, Nakano Y, *et al.* CT scan findings of emphysema predict mortality in COPD. *Chest* 2010;138:635–40.
6. From the *Global Initiative for Asthma Management and Prevention*. 2011. <http://www.ginasthma.org/> (accessed 20 June 2012).
7. Griffith DE, Aksamit T, Brown-Elliott BA, *et al.* ATS mycobacterial disease subcommittee. American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. *Am J Respir Crit Care Med* 2007;175:367–416.
8. Richerson HB, Bernstein IL, Fink JN, *et al.* Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. *J Allergy Clin Immunol* 1989;84:839–44.
9. Nakata K. Revision of clinical guidelines for diffuse panbronchiolitis. In: *Annual report on the study of diffuse lung disease in 1998. Grant in aid from the ministry of health and welfare of Japan*. Tokyo, 1999:109–11.
10. Vassallo R, Ryu JH, Schroeder DR, *et al.* Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. *N Engl J Med* 2002;346:484–90.
11. Hunninghake GW, Costabel U, Ando M, *et al.* ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. *Sarcoidosis Vasc Diffuse Lung Dis* 1999;16:149–73.
12. Tsuchiya Y, Takayanagi N, Sugiura H, *et al.* Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. *Eur Respir J* 2011;37:1411–17.
13. Devakonda A, Raoof S, Sung A, *et al.* Bronchiolar disorders: a clinical-radiological diagnostic algorithm. *Chest* 2010;137:938–51.
14. American Thoracic Society (ATS) and the European Respiratory Society (ERS). American Thoracic Society/the European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2002;165:277–304.
15. Naidich DP, McCauley DI, Khouri NF, *et al.* Computed tomography of bronchiectasis. *J Comput Assist Tomogr* 1982;6:437–44.
16. American Thoracic Society (ATS). Standardization of Spirometry, 1994 Update. *Am J Respir Crit Care Med* 1995;152:1107–36.
17. Kurashima K, Takayanagi N, Sato N, *et al.* High resolution CT and bronchial reversibility test for diagnosing COPD. *Respirology* 2005;10:316–22.
18. Brightling CE, Ward R, Goh KL, *et al.* Eosinophilic bronchitis is an important cause of chronic cough. *Am J Respir Crit Care Med* 1999;160:406–10.
19. Gibson PG, Henry RL, Thomas P. Noninvasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. *Eur Respir J* 2000;16:1008–15.
20. Snider G. Chronic obstructive pulmonary disease: a definition and implication of structural determinants of airflow obstruction for epidemiology. *Am Rev Respir Dis* 1989;140:S3–8.
21. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152:S77–121.
22. Marsh SE, Travers J, Weatherall M, *et al.* Proportional classifications of COPD phenotypes. *Thorax* 2008;63:761–7.
23. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? *Thorax* 2009;64:728–35.
24. Cottin V, Nunes H, Brillet PY, *et al.* Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *Eur Respir J* 2005;26:586–93.
25. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. *Am J Respir Crit Care Med* 1998;157:1658–65.
26. Bumbacea D, Campbell D, Nguyen L, *et al.* Parameters associated with persistent airflow obstruction in chronic severe asthma. *Eur Respir J* 2004;24:122–8.
27. Chalmers GW, MacLeod KJ, Thomson L, *et al.* Smoking and airway inflammation in patients with mild asthma. *Chest* 2001;120:1917–22.
28. Boulet LP, Lemire C, Archambault F, *et al.* Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. *Chest* 2006;129:661–8.
29. Panizza JA, James AL, Ryan G, *et al.* Mortality and airflow obstruction in asthma: a 17-year follow-up study. *Intern Med J* 2006;36:773–80.
30. Hospers JJ, Postma DS, Rijcken B, *et al.* Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. *Lancet* 2000;356:1313–17.

31. Nishimura M, Makita H, Nagai K, *et al*. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;185:44–52.
32. de Torres JP, Marin JM, Casanova C, *et al*. Lung cancer in patients with chronic obstructive pulmonary disease—incidence and predicting factors. *Am J Respir Crit Care Med* 2011;184:913–19.
33. Rosenberger A, Bickeboller H, McCormack V, *et al*. Asthma and lung cancer: a systemic investigation by the international lung cancer consortium. *Carcinogenesis* 2012;33:587–97.
34. Martinez-Garia MA, Soler-Cataluna JJ, Sanz YD, *et al*. Factors associated with bronchiectasis in patients with COPD. *Chest* 2011;140:1130–7.